Accreditation and support statement:

·   PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit.

·   This activity is supported by educational grant from GlaxoSmithKline.

Objectives

•   Review the guideline-recommended role of immune-based therapies in the management of endometrial cancer.

•   Discuss access to care, cost of care and cost-effectiveness of Immune checkpoint inhibitors in the treatment of endometrial cancer.

 Educational Objectives

·      Discuss currently available options for pre-exposure prophylaxis (PrEP) in the prevention of HIV.

·      Describe the role of pharmacists in improving PrEP uptake in the United States. 

Faculty:

Drew W. Cates, PharmD, AAHIVP,

Educational Manager

SynerGrx

Chamblee, Georgia 

Faculty, has the following financial relationships with commercial interests to disclose:

Speaker's Bureau: Gilead

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.07 CEU) under the ACPE universal activity number 0290-0000-22-338-H02-P. The activity is available for CE credit through July 29, 2023.

This activity is supported by an educational grant from ViiV.

• Introduction of faculty and disclosures: 
• Dr. Kathryn Maples is a clinical pharmacy specialist in multiple myeloma at the Winship Cancer Institute with Emory Healthcare in Atlanta, Georgia.
• Dr. Maples has the following relevant financial relationships with commercial interests to disclose: consultant for GlaxoSmithKline, Janssen, Karyopharm, and Sanofi.
• Accreditation and support statement: 
• PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit.
• This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

 https://www.pharmacytimes.org/courses/multiple-myeloma-pharmacists-as-therapy-experts

Educational Objectives

• Review the targetable mutations RET, MET, and KRAS, including associated agents for the treatment of metastatic non-small cell lung cancer (NSCLC)

• Discuss the ways a pharmacist may improve adherence, toxicity management, and outcomes for patients with metastatic NSCLC expressing RET, MET, and KRAS mutations

Josiah D. Land, PharmD, BCOP

Clinical Pharmacy Specialist – Thoracic Medical Oncology

Department of Pharmacy

Memorial Sloan Kettering Cancer Center

New York, New York

Josiah D. Land, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:

Consultant (advisory board): Bristol Myers Squibb

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number0290-0000-22-388-H01-P. The activity is available for CE credit through July 29, 2023.

This activity is supported by educational funding provided by Amgen.

Educational Objectives

·      Review the efficacy and safety of emerging frontline immune checkpoint inhibitor (ICI) used as monotherapy and in combination regimens

·      Indicate the impact of ICIs and programmed death-ligand 1 testing on cost-effectiveness and patient reported outcomes related with frontline use of ICIs in advanced NSCLC

Faculty:

Paul Forsberg, PharmD, MHA, BCOP

Director of Pharmacy

Minnesota Oncology

St. Paul, Minnesota

Latha Radhakrishnan, PharmD, BCOP

Clinical Oncology Pharmacist

The University of Illinois Hospital and Health Sciences System

Clinical Assistant Professor

University of Illinois at Chicago College of Pharmacy

Chicago, Illinois

Paul Forsberg, PharmD, MHA, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Epizyme

Speakers Bureau: AstraZeneca

Latha Radhakrishnan, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Taiho, Novartis, Exelixis

Speakers Bureau: BMS, AstraZeneca, Taiho, Exelixis

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-22-363-H01-P. The activity is available for CE credit through July 29, 2023.

This activity is supported by independent medical education grants from Merck Sharp & Dohme Corp., Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme.

 https://www.pharmacytimes.org/courses/continuing-the-conversation-optimizing-frontline-immunotherapy-outcomes-in-nsclc-and-managed-care-considerations

• Introduction of faculty and disclosures: 
• Dr. Kathryn Maples is a clinical pharmacy specialist in multiple myeloma at the Winship Cancer Institute with Emory Healthcare in Atlanta, Georgia.
• Dr. Maples has the following relevant financial relationships with commercial interests to disclose: consultant for GlaxoSmithKline, Janssen, Karyopharm, and Sanofi.
• Accreditation and support statement: 
• PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit.
• This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

https://www.pharmacytimes.org/courses/multiple-myeloma-recognizing-treatment-options

Educational Objectives

·      Understand the impact of Janus kinase inhibitors for the management of atopic dermatitis (AD)

·      Examine key safety and efficacy data on new and emerging Janus kinase inhibitors utilized for the treatment of AD and select appropriate treatments

• Identify the role of the pharmacist in individualizing treatment for patients with AD through patient counseling and education

Faculty:

Svetlana Gerzenshtein, PharmD, BCPS, CSP

Clinical Pharmacist Specialist

Specialty Pharmacy Department

University of Chicago Medical Center

Chicago, Illinois

Content Development

Sarah Lant, PharmD

Clinical Pharmacist Specialist

UChicago Medicine

Chicago, Illinois

Svetlana Gerzenshtein, PharmD, BCPS, CSP, has no financial relationships with commercial interests to disclose.

Sarah Lant, PharmD, has the following relevant financial relationship with a commercial interest to disclose:

Other (faculty speaker training): Lily

Educational Objectives

·      Recognize the role of biomarker expression in the selection of most appropriate treatment options for patients with endometrial cancer

·      Review strategies for identification and management of drug-related toxicities in patients receiving therapy with immune checkpoint inhibitors, targeted agents, or combination therapy

Faculty:

Sarah Hayward, PharmD, BCOP

Clinical Pharmacy Specialist, Gynecologic Oncology

Stephenson Cancer Center at OU Health

University of Oklahoma Health Science Center

Oklahoma City, Oklahoma

Sarah Hayward, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Consultant (advisory board): GSK, Seagen/Genmab

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-322-H01-P. The activity is available for CE credit through June 30, 2023.

This educational activity is supported by an educational grant from GlaxoSmithKline

• Introduction of faculty and disclosures: 
• Dr. Katherine Tobon is a clinical pharmacy specialist in malignant hematology with Moffitt Cancer Center in Tampa, Florida.
• Dr. Tobon has no relevant financial relationships with commercial interests to disclose.
• Accreditation and support statement: 
• PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit.
• This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., Administered by Janssen Scientific Affairs, LLC and BeiGene, Ltd.

• Introduction of faculty and disclosures: 
• Dr. Katherine Tobon is a clinical pharmacy specialist in malignant hematology with Moffitt Cancer Center in Tampa, Florida.
• Dr. Tobon has no relevant financial relationships with commercial interests to disclose.
• Accreditation and support statement: 
• PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit.
• This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., Administered by Janssen Scientific Affairs, LLC and BeiGene, Ltd.

This podcast will specifically focus on clinical safety and efficacy data supporting the use of new and emerging JAK inhibitors in the management of AD. Practical counseling points for pharmacists to provide individualized care and proper selection of therapy to patients with AD who are initiating therapy with JAK inhibitors will also be discussed. Faculty experts will review audience questions and identify best practices in the management of AD.

o  The Role of JAK Inhibitors in the Management of Atopic Dermatitis: Latest Advances and Best Practices for the Pharmacist

o  Introduction of faculty, affiliations, and disclosures

We would like to thank Sarah Lant, PharmD for her contribution in developing the content for this podcast.

Lana Gerzenshtein, PharmD and Sarah Lant have no relevant financial relationships with commercial interests to disclose.

o  Accreditation and support statement

PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit.

This activity is supported by educational grants from Incyte.

 Lisa Dumkow, PharmD, BCIDP, Antimicrobial Stewardship Clinical Pharmacist, PGY-2 Infectious Diseases Pharmacy Residency Program Director, Mercy Health Saint Mary’s, Grand Rapids, MI

Lacy Worden, PharmD, PGY-2 Infectious Diseases Pharmacy resident, Mercy Health Saint Mary’s, Grand Rapids MI [LP1] 

Dr. Dumkow & Dr. Worden have no relevant financial relationships with commercial interests to disclose

PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour of knowledge-based credit.

This activity is supported by educational grants from GlaxoSmithKline.

    The educational objectives for this activity are:

o  Examine important milestones and recent updates in the treatment and management of COVID-19

o  Interpret safety and efficacy data for recently approved, authorized, or investigational agents for the treatment of COVID-19

o  Illustrate how pharmacists can assist with educating patients and other health care providers regarding the latest updates to the treatment of COVID-19

Summary statement of topic being discussed: This is a conversational interview which will focus on emerging therapies for the management of COVID-19 in the outpatient setting. A discussion around current and investigational therapies will be covered. Key takeaways and practical points will be the focus.

Educational Objectives

• Examine challenges in current treatment options for seizure clusters, including efficacy and safety, and differentiating routes of administration
• Highlight considerations in treatment of seizure clusters, including addressing barriers to treatment and providing patient counseling to improve outcomes

Faculty:

Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FCCM, FNCS, MCCM 

Professor

Departments of Pharmacotherapy & Outcomes Science and Neurosurgery

Virginia Commonwealth University, Medical College of Virginia

Richmond, Virginia

Neurocritical Care Clinical Pharmacist

Virginia Commonwealth University Health

Richmond, Virginia

Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FCCM, FNCS, MCCM, has the following relevant financial relationships with commercial interests to disclose:

• Grant/Research Support: Department of Defense
• Consultant: UCB, Chiesi, Marinus, Alexion, Ceribell
• Speakers Bureau: UCB, Chiesi

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-129-H01-P. The activity is available for CE credit through March 31, 2023.

This activity is supported by an educational grant from Neurelis Inc.

Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FNCS, MCCM is Professor of Pharmacotherapy & Outcomes Sciences and Neurosurgery at Virginia Commonwealth University (VCU) School of Pharmacy, Medical College of Virginia Campus. She is a Past President of the Neurocritical Care Society. Dr. Brophy’s research interests include neuropharmacotherapy, traumatic brain injury, biomarkers, hemostasis, stroke, and status epilepticus.

Educational Objectives

• Describe the impact of ADHD and new non-stimulant class of ADHD treatments
• Highlight the role of the pharmacist in patient counseling, monitoring and medication management in ADHD

Faculty:

Sandy Mullen, PharmD, BCPP

Clinical Pharmacy Specialist - Child and Adolescent Psychiatry 

Department of Pharmacy 

Virginia Commonwealth University (VCU) Health

Richmond, VA

Sandy Mullen, PharmD, BCPP, has no financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-22-127-H01-P. The activity is available for CE credit through March 30, 2023.

This activity is supported by an educational grant from Supernus.

Educational Objectives

• Review the clinical and economic burdens associated with transthyretin amyloidosis (ATTR)

• Recall key characteristics supporting the use of current and emerging therapies for the treatment of ATTR including mechanisms of action, clinical data, dosing, administration, and potential adverse effects

Faculty:

Svetlana Goldman, PharmD, BCACP, CDCES

Clinical Pharmacist

UC Davis Health

Sacramento, California

Yvette Hellier, PharmD, BCACP

Clinical Pharmacist

UC Davis Health

Sacramento, California

The following contributors have no relevant financial relationships with commercial interests to disclose: 

Faculty

Svetlana Goldman, PharmD, BCACP, CDCES, and Yvette Hellier, PharmD, BCACP

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-22-045-H01-P. The activity is available for CE credit through February 28, 2023.

This activity is supported by an educational grant from Alnylam Pharmaceuticals.

Educational Objectives

• Describe the impact of COVID-19 on surgical pain management 
• Review current postoperative pain management guidelines and emerging non-opioid treatment approaches for pain management, including safety and efficacy data on newer treatments, and key considerations for pharmacists

Faculty:

Jawad N. Saleh, PharmD, BS, BCPS, BCCCP

Clinical Manager of Pharmacy Services

Pharmacy Department

The Hospital for Special Surgery

New York, New York

Faculty, has the following financial relationships with commercial interests to disclose:

Jawad N. Saleh, PharmD, BS, BCPS, BCCCP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Heron Therapeutics, Baudax Bio

Speakers Bureau: Heron Therapeutics, Baudax Bio

Scientific Advisory Boards: Heron Therapeutics, Baudax Bio

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-22-046-H08-P. The activity is available for CE credit through February 24, 2023.

This activity is supported by an educational grant from Heron.

Educational Objectives

• Discuss the role of disruptions in the gut microbiome in the development of Clostridioides difficile infection (CDI) and recurrent CDIs
• Review the efficacy, safety, and role of fecal microbiota transplantation and emerging microbiome-based drugs for treatment of CDIs and rCDIs

Faculty:

Kevin W. Garey, PharmD, MS

Professor and Chair

University of Houston College of Pharmacy 

Houston, Texas

Kevin W. Garey, PharmD, MS, has the following relevant financial relationships with commercial interests to disclose:

Grant/Research Support: Summit, Acurx, and Parakek Pharmaceuticals, and Seres Therapeutics

Consultant: Ferring Pharmaceuticals

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-22-048-H01-P. The activity is available for CE credit through January 31, 2023.

This activity is supported by a medical education grant from Ferring Pharmaceuticals.

Participants can claim credit for this CE activity by following the link below:

https://www.pharmacytimes.org/courses/the-promising-role-of-microbiome-based-drugs-for-the-treatment-and-prevention-of-recurrent-clostridioides-difficile

Educational Objective

• Identify best practices for managing toxicities associated with therapies for the treatment of Waldenström macroglobulinemia

Faculty: Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Ambulatory Hematology Oncology

University of Michigan Rogel Cancer Center

Clinical Assistant Professor

University of Michigan College of Pharmacy

Ann Arbor, Michigan

Faculty has no financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-21-457-H01-P. The activity is available for CE credit through June 20, 2022.

This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc; and BeiGene, Ltd.

Educational Objectives

·            Recognize best practices for managing adverse effects associated with immune checkpoint inhibitor (ICI)-targeted therapy combinations

Faculty:

Jacob K. Kettle, PharmD, BCOP

Pharmacy Manager

Ellis Fischel Cancer Center

Department of Pharmacy

University of Missouri Health Care

Columbia, Missouri

Faculty, has the following financial relationships with commercial interests to disclose:

Jacob Kettle, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Speakers Bureau: Genentech, Merck, Amgen, Lilly, DSI

Consultant: Pfizer, Lilly

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-21-438-H01-P. The activity is available for CE credit through December 17, 2022.

This activity is supported by educational grants from Eisai Inc and Exelixis, Inc.

Educational Objectives

·             Describe the role of immune checkpoint inhibitor (ICI)-targeted therapy combinations across malignancies

·             Recall knowledge of ICI-targeted therapy combinations to treatment selection in patients with cancer

Faculty:

Jacob K. Kettle, PharmD, BCOP

Pharmacy Manager

Ellis Fischel Cancer Center

Department of Pharmacy

University of Missouri Health Care

Columbia, Missouri

Faculty, has the following financial relationships with commercial interests to disclose:

Jacob Kettle, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Speakers Bureau: Genentech, Merck, Amgen, Lilly, DSI

Consultant: Pfizer, Lilly

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-21-437-H01-P. The activity is available for CE credit through December 17, 2022.

This activity is supported by educational grants from Eisai Inc and Exelixis, Inc.

Pharmacy Times Continuing Education™ (PTCE) provides industry-leading pharmacy CE to retail, oncology, managed care, specialty, and health-system pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education.

Podcast 1: Waldenström Macroglobulinemia and Treatment Advancements with the Use of BTK Inhibitors

Educational Objectives

·             Outline the pathophysiology of Waldenström macroglobulinemia (WM) and its connection to use of new and emerging drug therapies

·             Review clinical guidelines and treatment selection in patients with WM

Faculty: Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Ambulatory Hematology Oncology

University of Michigan Rogel Cancer Center

Clinical Assistant Professor

University of Michigan College of Pharmacy

Ann Arbor, Michigan

Faculty has no financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-21-441-H01-P. The activity is available for CE credit through June 13, 2022. 

This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc; and BeiGene, Ltd.

Optimizing Care for People Living with HIV: Beyond Typical Risk Factors for Weight Gain | PTCE Connect Educational Objectives Describe recent data surrounding weight gain among people living with HIV (PLWH) who are on antiretroviral therapy Recognize the role of the pharmacist in the care of PLWH Continuing the Conversation – Individualizing the Management of HIV: A Focus on Weight Gain Introduction of faculty, affiliations, and disclosures Dr. David Koren, PharmD, MPH, BCPS, AAHIVP, Clinical Pharmacist Specialist in Infectious Diseases at the Temple University Health System, Philadelphia, Pennsylvania Dr. Koren has the following relevant financial relationships with commercial interests to disclose: Advisory Boards: Gilead, Thera, and ViiV Independent consulting: AbbVie and Thera Accreditation and support statement PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 credit hours of knowledge-based credit. This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP. Access PTCE here: https://www.pharmacytimes.org/on-demand/continuing-the-conversation-individualizing-the-management-of-hiv-a-focus-on-weight-gain See omnystudio.com/listener for privacy information.